5

10

## **CLAIMS**

- 1. A method of stereospecifically preparing a 3-hydroxy-5β-H steroidal sapogenin or a derivative thereof, which comprises reducing a 3-keto-5β-H steroidal sapogenin using a reducing agent comprising a hindered organoborane or an organo-aluminium hydride.
- 2. A method according to claim 1, wherein the reducing agent is a hindered organoborane reagent in which organic groups contain more than two carbon atoms and the sapogenin obtained is predominantly a  $3\beta$ -hydroxy,  $5\beta$ -H-sapogenin.
- A method according to claim 1 or claim 2, wherein hindered organoborane is selected from lithium tri-sec-butylborohydride, potassium tri-sec-butylborohydride, lithium trisiamylborohydride, potassium trisiamylborohydride, potassium triphenylborohydride and lithium triphenylborohydride.
- 4. A method according to claim 3, wherein the hindered organoborane is lithium tri-sec-butylborohydride.
  - 5. A method according to claim 1, wherein the organo-aluminium hydride is lithium tri-tert-butoxyaluminohydride.
- 25 6. A method according to any one of the preceding claims, wherein the molar ratio of the predominant sapogenin obtained to the alternative 3-epimer, is at least about 10:1.

- 7. A method according to claim 6, wherein the ratio is at least about 15:1.
- 8. A method according to any one of the preceding claims, when performed in an organic solvent selected from tetrahydrofuran, toluene, *tert*-butyl methyl ether, diethoxymethane, 1,4-dioxan, 2-methyltetrahydrofuran and any mixture thereof.
  - 9. A method according to claim 8, wherein the organic solvent consists essentially of tetrahydrofuran.

10

5

- 10. A method according to claim 8, wherein the organic solvent consists essentially of toluene.
- 11. A method according to claim 8, wherein the organic solvent consists essentially of 1,4-dioxan.
  - 12. A method according to claim 8, wherein the organic solvent consists essentially of 2-methyltetrahydrofuran.
- 20 13. A method according to any one of the preceding claims, wherein the desired sapogenin is a compound of general formula.

wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $R_8$  and  $R_9$  are, independently of each other, H,  $C_{1-4}$  alkyl, OH, or OR (where  $R = C_{6-12}$  aryl or  $C_{1-4}$  alkyl), or  $R_5$  and  $R_6$  together may represent a = O (carbonyl) or protected carbonyl group,

- the stereochemistry at carbon centre 3 can be either R or S, and R<sub>10</sub> represents OH, an O-linked sugar group or any organic ester group.
  - 14. A method according to claim 13, wherein the sapogenin is selected from sarsasapogenin, episarsasapogenin, smilagenin, epismilagenin and esters thereof.

10

15

- 15. A method according to any one of the preceding claims, wherein the 3-keto,5 $\beta$ -H steroidal sapogenin starting material is prepared by heterogeneous catalytic hydrogenation of a corresponding  $\Delta^4$ , 3-keto steroidal sapogenin to convert the  $\Delta^4$ , 3-keto steroidal sapogenin at least predominantly to the said 5 $\beta$ -H, 3-ketone.
- 16. A method according to claim 15, wherein the heterogeneous catalytic hydrogenation is performed using hydrogen and a palladium catalyst in an organic solvent.

20

- 17. A method according to claim 16, wherein the palladium catalyst is present on a support.
- 18. A method according to any one of claims 15 to 17, wherein the  $\Delta^4$ , 3-keto 25 steroidal sapogenin is diosgenone.
  - 19. A method according to claim 18, wherein the diosgenone is obtained by oxidation of diosgenin.

5

- 20. A method for the conversion of  $3\alpha$ -hydroxy- $5\beta$ -H steroidal sapogenins and derivatives thereof to  $3\beta$ -hydroxy- $5\beta$ -H steroidal sapogenins and derivatives thereof, which comprises contacting a 3-hydroxy-activated derivative of a  $3\alpha$ -hydroxy- $5\beta$ -H steroidal sapogenin with a nucleophile under conditions favouring nucleophilic substitution with inversion at the 3-position, with optional subsequent adjustment of the 3-substituent as desired.
- 21. A method according to claim 20, wherein the reaction is performed according to the Mitsonobu reaction protocol, to yield an ester derivative of the 3β-hydroxy-5β-H steroidal sapogenin.
  - 22. A method according to claim 20, wherein the activated derivative of the sapogenin is an organic sulphonated derivative.

15

- 23. A method for the synthesis of smilagenin, comprising catalytic hydrogenation of diosgenone followed by reduction of the resulting 3-keto,  $5\beta$ -H steroidal sapogenin using a hindered organoborane.
- 24. A method for the synthesis of epismilagenin, comprising catalytic hydrogenation of diosgenone followed by reduction of the resulting 3-keto,5β-H steroidal sapogenin using an organoalumino-hydride.
- 25. A method according to any one of the preceding claims, wherein a
  25 sapogenin initially formed is subsequently converted to a pro-drug form thereof or to another physiologically acceptable form thereof.